Figure 1

Kaplan-Meier Overall survival curves. A: Overall survival comparison among histological types. Endometrioid vs. Mucinous (Log-Rank p = 0.562; HR = 1.31; CI95% = 0.48-3.82); Endometrioid vs. Serous (Log-Rank p = 0.152; HR = 2.12; CI95% = 0.76-5.89); Serous vs. Mucinous (Log-Rank p = 0.421; HR = 1.53; CI95% = 0.54-4.35). B: Overall survival comparison among FIGO stages. I vs. II (Log-Rank p = 0.452; HR = 2.16; CI95% = 0.29-16.28); I vs. III (Log-Rank p = 0.033; HR = 3.07; CI95% = 1.09-8.61); I vs. IV (Log-Rank p = 0.0003; HR = 12.56 CI95% = 3.19-49.46); II vs. III (Log-Rank p = 0.458; HR = 1.63; CI95% = 0.45-5.95); II vs. IV (Log-Rank p = 0.025; HR = 4.40; CI95% = 1.20-16.13); III vs. IV (Log-Rank p = 0.055; HR = 2.87; CI95% = 0.97-8.45). C: Overall survival comparison among groups of age at diagnosis. 40 years old or less vs. 41 to 60 years old (Log-Rank p = 0.170; HR = 2.04; CI95% = 0.73-5.64); 40 years old or less vs. above 60 years old (Log-Rank p = 0.018; HR = 2.91; CI95% = 1.20-7.04); 41 to 60 years old vs. above 60 years old (Log-Rank p = 0.057; HR = 1.817; CI95% = 0.98-3.36). D: Overall survival comparison among adjuvant treatment regimens. Platinum only vs. Platinum-Paclitaxel (Log-Rank p = 0.347; HR = 2.02; CI95% = 0.46-8.80); Platinum only vs. Platinum-Ciclophosphamide (Log-Rank p = 0.499; HR = 1.89; CI95% = 0.30-1.99); Platinum-Paclitaxel vs. Platinum-Ciclophosphamide (Log-Rank p = 0.633; HR = 1.31; CI95% = 0.43-4.00).